Navigation Links
Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor

Cancer Targeted Therapeutic for Samtheo's Personalized Medicine Portfolio

NEW YORK, March 16 /PRNewswire/ -- Samtheo Biopharma LLC has entered into a license agreement, through its subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, gaining exclusive worldwide rights to a small molecule that selectively inhibits the activation of all three isoforms of Akt. Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation, survival and invasiveness

Co-inventors are Jin Q. Cheng, M.D., Ph.D. and Said M. Sebti, Ph.D. from Moffitt. "This small molecule is a highly selective and potent inhibitor of Akt activation, leading to tumor growth arrest and induction of cancer cell death, and results in overcoming chemoresistance," said Dr. Cheng, Professor, Molecular Oncology Department at Moffitt. "Patients whose tumors contain persistently activated Akt are predicted to be more likely to respond to this inhibitor either as a single agent or in combination therapy," said Dr Sebti, Professor and Chair, Drug Discovery Department at Moffitt. "Akt is abnormally hyperactivated in many advanced malignancies and late stage tumors, such as breast, prostate, lung, pancreatic, liver, ovarian and colorectal cancers. Increased activation is also linked with drug and radiation resistance," said Dr. Cheng.

Through this license, Lyndor plans to develop and commercialize the new anti-cancer agent, which it refers to as LD-101, for refractory and resistant tumors as well as metastatic malignancies, addressing a huge unmet medical need. "Given time, most cancers will relapse, become resistant and, ultimately, refractory. In fact, most become metastatic before detection," said Susan Rosenbaum, Esq., Chairman and CEO of Samtheo. "Lyndor's agreement with Moffitt will enable Lyndor to develop this targeted therapeutic for personalized medicine in the treatment of patients with these difficult-to-treat diseases." Under the license agreement, Lyndor has agreed to pay Moffitt when various milestones are reached and provide Moffitt with running royalties on the sales of licensed products.

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center ( is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control.

About Lyndor

Lyndor is a privately-held subsidiary of Samtheo that acquired the exclusive, world-wide rights to its lead compound, LD-101, from Moffitt. Lyndor's interest in the treatment of cancer and development of LD-101 as an effective targeted therapeutic agent for personalized medicine is propelled by the desire to improve cancer treatment, offer patients greater life expectancy and provide a better quality of life.

About Samtheo

Samtheo is a privately-held company that invests in biotechnology companies focused on the delivery of personalized medicine through targeted therapeutics. Samtheo is in the business of acquisition, development and commercialization of innovative technology "with integrity", i.e., proprietary, novel intellectual property that will generate evidence-based, medically-effective and socially-assessable products. Samtheo's global mission is to improve health care and outcomes dramatically for patients with life-threatening diseases and unmet medical needs. Samtheo's press releases and other company information are available at

SOURCE Samtheo Biopharma LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Neurocrine ... Kevin Gorman , President and CEO of Neurocrine ... Jaffray Healthcare Conference in New York ... encouraged to visit the website approximately 5 minutes prior ... software.  A replay of the presentation will be available ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Connected health pioneer, Joseph C. Kvedar , MD, ... and wellness, and the business opportunities that arise from ... of Healthy Things . Long before health and ... Kvedar, vice president, Connected Health, Partners HealthCare, was creating ... from the hospital or doctor,s office into the day-to-day ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... today announced that Google has adopted the Synaptics ® ... controller solutions to power its newest flagship smartphones, the ... Huawei. --> --> ... Google to provide strategic collaboration in the joint development ...
Breaking Biology News(10 mins):